What Finimal Treats: Main Uses and Benefits

The primary therapeutic role of this medication is to provide symptomatic relief across key domains of acute discomfort, supporting patient comfort during periods of noticeable symptom expression. The therapeutic scope includes its use for managing many painful and febrile conditions, including headache and symptoms associated with influenza.

This medicine is commonly used to help with symptoms related to physical discomfort, for managing common discomforts, which include episodic headache, acute episodes of migraine, toothache, general musculoskeletal aches, and discomforts related to menstrual pain (dysmenorrhea). It is applied across domains where additional symptomatic support is needed, particularly when dealing with symptoms related to systemic imbalance, like fever and generalized body aches associated with the common cold or flu.

Applied in contexts where short-term symptomatic assistance is appropriate, the combination formulation supports patients and may assist with easing the overall intensity of these acute or episodic manifestations, and may contribute to improved comfort during symptomatic periods.

---

Key Therapeutic Role

The medication is relevant for easing symptoms that cluster around mild to moderate pain and febrile states, offering symptomatic support during acute episodes of discomfort and common illness.

---

Finimal is a combination analgesic and antipyretic medication that typically contains paracetamol (acetaminophen) and caffeine. Specific formulations may vary by country, with some historical or regional versions also containing propyphenazone. The drug is generally suitable for adults and children over the age of 6 or 12, depending on the specific product formulation.

---

Contraindications (Who Should Not Use Finimal)

Finimal is generally contraindicated (should not be used) in individuals with a known hypersensitivity or allergy to paracetamol, caffeine, or any other components in the formulation.

Due to the paracetamol component and the risk of hepatotoxicity, it must be avoided by those with:

• Severe hepatic impairment (severe liver disease) or acute hepatitis.
• Chronic, excessive alcohol consumption.

Additional contraindications may apply to specific formulations, particularly those containing propyphenazone (a pyrazolone derivative).

---

Precautions (Use with Caution)

Caution is advised, and medical consultation is necessary, for individuals with the following conditions:

• Mild to moderate hepatic impairment or renal impairment (kidney function problems).
• Gilbert's syndrome, glucose-6-phosphate dehydrogenase (G6PD) deficiency, or hemolytic anemia.
• Dehydration, underweight, or malnutrition.
• Concurrent use of other paracetamol-containing products to avoid accidental overdose.
• Pregnancy and breastfeeding, where the benefits must be weighed against potential risks, and medical advice should be sought.

Finimal, which contains paracetamol (acetaminophen), has officially documented interactions with several categories of medicinal products and substances. It is required to avoid co-administering the product with any other medicine that contains acetaminophen due to the risk of severe liver toxicity.

Documented Drug Interactions

The most clinically significant drug interaction is with anticoagulant drugs such as warfarin. The regulatory information indicates that the dosage of the anticoagulant may require reduction if paracetamol is taken for a prolonged period, as this combination can alter the International Normalized Ratio (INR), a measure of blood clotting.

Interacting Product/Category	Practical Constraint/Effect
Colestyramine (Bile acid sequestrant)	Reduces paracetamol absorption if administered within one hour of this product.
Metoclopramide (Prokinetic)	May increase the rate of paracetamol absorption.
Propantheline (Anticholinergic)	May decrease the rate of paracetamol absorption.
Chloramphenicol (Antibiotic)	Paracetamol may increase chloramphenicol concentrations.
Liver enzyme inducers (e.g., certain anticonvulsants) and Alcohol	May increase the risk of paracetamol toxicity.

The risk of severe liver damage is also tied to taking this product while consuming three (3) or more alcoholic drinks daily, a condition explicitly noted in regulatory documents. Additionally, probenecid may affect the body's excretion of paracetamol and alter its plasma concentrations. Clinicians should observe these warnings to manage potential complications.

Finimal is a proprietary combination drug. The primary mechanistic component, paracetamol (acetaminophen), acts predominantly within the central nervous system (CNS). It functions as an inhibitor, reducing prostaglandin synthesis via inhibition of cyclooxygenase (COX) enzymes, particularly COX-2, under low substrate concentrations.

A significant secondary pathway involves its active metabolite, AM404, which is formed in the CNS. AM404 is an agonist at the Transient Receptor Potential Vanilloid 1 (TRPV1) receptor and an inhibitor of the reuptake of the endocannabinoid anandamide ( AEA). The resulting activation of the TRPV1 receptor and enhancement of AEA signaling contribute to the downstream modulation of descending serotonergic neuronal pathways. This cumulative molecular activity modifies central nociceptive signal transduction and thermoregulatory set-points.

The secondary component, caffeine, acts as a non-selective antagonist of adenosine ( A1 , A2 A , A2 B , and A3 ) receptors within the CNS. This antagonism modifies general neurotransmission and cerebral vascular tone, further influencing the systemic physiological state.

Administration Guidelines

Finimal is administered via the oral route as a solid tablet and must be swallowed with water. The medicine may be taken with or without food; administration without food may accelerate the onset of action.

Feature	Instruction / Labeled Rule
Standard Single Dose	Adults/Adolescents ge 16 Years: 1000 mg Paracetamol (two tablets). Adolescents 12–15 Years: 500 mg Paracetamol (one tablet).
Maximum Daily Dose	Must not exceed 4000 mg Paracetamol in 24 hours. A reduced maximum of 2000 mg is specified for individuals weighing < 50 kg or with chronic alcoholism.
Dosing Interval	A minimum interval of 4 hours must be maintained between doses, with the total frequency not exceeding four doses per 24 hours.

Procedural Constraints and Duration

Standardized use protocols center on strict dose control and short-term use. The medicine is intended to be used for the shortest time possible, and treatment should not continue for longer than 3 days for fever or 5 days for pain without consultation. The protocol strictly forbids the concurrent use of any other product containing Paracetamol to prevent accidental exceedance of the daily maximum, which is a mandatory administration constraint.

Summary of Clinical Trials

Research has explored whether this combined treatment is associated with reported changes in key symptoms, such as headache and postoperative pain. Studies included an exploration of potential biological pathways. A key focus of the research involves the combination of paracetamol (acetaminophen) and caffeine, which is the formulation of Finimal.

A meta-analysis evaluating the combination of paracetamol and caffeine across various acute pain states compared outcomes to paracetamol alone. The analysis included data from several randomized, double-blind trials.

Dosing and Administration in Research

Studies generally focused on adults without specific pre-existing conditions, such as severe kidney issues or certain neurological disorders. Research protocols typically involved starting with a lower dosage before escalating to a standard therapeutic dose.

The most common protocol evaluated the paracetamol component at a daily dosage of X mg (milligrams), often administered in divided doses. Trial designs emphasized adherence to the specific dose ratio of the active components.

Reported Safety and Side Effects

Safety data from Phase III clinical trials included reporting on serious adverse events. Reported side effects in studies included events described as mild and temporary. Reported outcomes were based on aggregated study findings. The most frequently reported adverse effects included:

• Mild fatigue
• Temporary nausea
• Headache

Combination Therapy Research

Further studies evaluated the combination of the active components with other treatments. Research explored whether the combination was associated with changes in pain scores compared to monotherapies (single drug use) in settings like tension-type headache. The research objectives focused on evaluating patient ratings of pain intensity reduction. Some studies reported patient ratings of pain intensity reduction within the first week of use.

Key Studies & References

1. NICE Guideline for Low Back Pain and Sciatica (Used for context on paracetamol monotherapy effectiveness)

Common questions about Finimal (FAQ)

Q: Is Finimal considered a type of anti-inflammatory medicine?

Official regulatory documents state that paracetamol, the primary ingredient, is classified as an analgesic (pain-reliever) and an antipyretic (fever-reducer). While the mechanism involves inhibiting certain enzymes, official information confirms that the drug does not possess useful anti-inflammatory activity.

Q: Why is Finimal prescribed for a wide range of uses?

The combination is widely used because its official indication is the symptomatic relief of various types of mild to moderate aches, pains, and fever. These include common symptoms associated with headaches, muscle pain, backache, and discomfort related to colds and flu.

Q: Is Finimal effective for chronic pain management, according to research?

Regulatory guidelines emphasize that this product is intended for acute, short-term use only. Official documents state that treatment continuation beyond a few days requires consultation with a healthcare professional. Prolonged or frequent use is discouraged due to potential risks, such as developing a medication-overuse headache.

Q: Does Finimal cause drowsiness or affect concentration?

Regulatory warnings caution that side effects may include dizziness or drowsiness, which could temporarily affect concentration. Conversely, the caffeine component is a central nervous system stimulant that can cause nervousness or sleeplessness.

Q: What signs indicate a need to consult a healthcare provider about Finimal side effects?

Immediate medical advice is required if signs of severe adverse events are noticed, such as jaundice (yellowing of the skin or eyes), which indicates potential liver damage. It is noted that urgent attention is sought for symptoms of a severe allergic reaction, such as difficulty breathing or swelling. This guidance is crucial even if a suspected overdose has occurred and the individual feels well.

Q: How long does it typically take for Finimal to begin working?

Regulatory-cited data indicates that the combination with caffeine accelerates the absorption of the primary pain-relieving ingredient, paracetamol. This is designed to contribute to a faster onset of pain relief compared to using paracetamol alone.

Q: Can individuals with a history of heart issues safely use Finimal?

According to the official product information, the medicine is contraindicated (must not be taken) by individuals who have high blood pressure or an irregular or rapid heart beat. This constraint is due to the stimulating effects of the caffeine component in the combination product.

Q: What is the research evidence for Finimal's long-term safety profile?

Regulatory guidance discourages prolonged or frequent use and restricts the maximum treatment duration. This constraint is in place due to the potential risk of liver damage and other severe side effects.

Q: What is the meaning of a 'contraindication' related to Finimal?

A contraindication is a clear instruction in official product information stating that you must not take the medicine if you have a specific health condition or are taking a certain co-medication. The official label lists these constraints because the potential risk of serious harm is judged to be greater than any expected benefit in those specific circumstances.

Q: Does Finimal interact with common dietary or herbal supplements?

Regulatory guidance includes information about limiting overall intake of caffeine from all sources, including coffee, tea, and other supplements. This is recommended to prevent caffeine-related side effects such as rapid heart rate, nervousness, or sleeplessness.

Q: Can Finimal be taken safely with blood pressure medications?

Official product information states that the medicine is contraindicated (must not be taken) if you are taking medication for high blood pressure, such as beta-blockers. This constraint is due to the potential stimulating effects of the caffeine component.

Q: Does Finimal affect the effectiveness of hormonal birth control?

The paracetamol component is generally considered to pose no significant additional risk to the effectiveness of hormonal birth control pills at usual therapeutic doses. However, official information notes that oral contraceptives may slow the breakdown of the caffeine component, potentially prolonging its stimulating effects.

Q: What does the official guidance say about missing a scheduled dose of Finimal?

Official guidance exists regarding managing a missed dose when the product is taken on a regular dosing schedule. This guidance addresses taking the dose when remembered and notes conditions under which the dose should be skipped to prevent a double dose.

Q: Is Finimal generally considered appropriate for people over the age of 65?

Dosage instructions are provided for adults, but regulatory documents advise that older patients may be more sensitive to the effects of pain medicines. Caution is generally warranted, particularly if there are pre-existing conditions common in the elderly, such as kidney or liver impairment.

Q: Are there any official warnings about operating machinery or driving while using Finimal?

Official warnings state that the medicine may impair your ability to drive a motor vehicle or operate machinery. This caution is based on potential side effects like dizziness, excitability, or sleep disturbances.

How to Store and Dispose of Finimal

Official regulatory documents define specific, mandatory requirements for storing and disposing of Finimal (Paracetamol/Caffeine) tablets.

---

Storage Requirements

Finimal generally requires storage under ordinary conditions, typically meaning below 25 C. The product must be stored in the original package to ensure protection from moisture and light, which is standard for oral solid dosage forms. As a mandatory requirement, the medication must always be kept out of the sight and reach of children.

Disposal Instructions

Do not dispose of Finimal via household waste or by flushing it into wastewater. Unused or expired medication must be discarded in accordance with local requirements for pharmaceutical waste handling.